Cancer is complex and can be a devastating diagnosis for individuals and their families. Our researchers work to improve cancer control on many levels, from prevention and screening through treatment and survivorship.
Kaiser Permanente Washington Health Research Institute (KPWHRI) has been studying how to provide life-saving breast cancer screening since 1986. In a novel initiative, researchers used a computer-based registry and collaborations with organizations across the U.S. before electronic health records existed and multi-site studies were common. The program ultimately led to a rich portfolio of studies not only on breast cancer, but also on colorectal, blood, cervical, lung, and thyroid cancers.
“Decades later, Kaiser Permanente Washington is just as committed to developing and evaluating innovations in cancer care,” said Karen Wernli, PhD, KPWHRI senior investigator.
The core of KPWHRI cancer research lies in its participation in many collaborative networks and programs. “Collaboration increases the power of Kaiser Permanente studies and helps us learn from different populations and health care settings,” said Senior Investigator Jessica Chubak, PhD. Examples of these networks include:
Breast Cancer Surveillance Consortium (BCSC)
The BCSC identifies strategies that detect aggressive breast cancer early, minimize harms, and reach diverse communities. Results help policymakers and health systems improve breast cancer screening and surveillance outcomes. The Kaiser Permanente Washington Breast Imaging Registry contributes to this national effort and the BCSC Statistical Coordinating Center resides at KPWHRI.
Population-based Research to Optimize the Screening Process (PROSPR)
The PROSPR national consortium conducts research to improve screening for cervical, colorectal, and lung cancers. PROSPR results will help optimize and tailor screening for different subgroups of the population.
Kaiser Permanente Research Bank (KPRB) Cancer Cohort
The KPRB Cancer Cohort is a national resource for understanding genetic, lifestyle, and environmental factors that contribute to cancer etiology and survival. Electronic health record data, stored tissue specimens, detailed treatment data, and the ability to follow patients for recurrence and mortality are accelerating progress toward improved cancer care.
Some of the cancer research group’s current studies include:
Past findings include:
Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancetf J, Brand L, Field T, Ayala E, Janssen W, List AF, Anasetti C. Severe hypoalbuminemia at day 90 predicts worse non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2011 Mar;17(3):384-93. Epub 2010 Jul 22. PubMed
Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, Perez EA, Lew D, Livingston RB. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol. 2011 Mar 10;29(8):1014-21. Epub 2011 Jan 10. PubMed
Coghill AE, Newcomb PA, Chia VM, Zheng Y, Wernli KJ, Passarelli MN, Potter JD. Pre-diagnostic NSAID use but not hormone therapy is associated with improved colorectal cancer survival in women. Br J Cancer. 2011 Mar 1;104(5):763-8. Epub 2011 Feb 8. PubMed
Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, Li CI. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control. 2011 Mar;22(3):399-405. Epub 2010 Dec 24. PubMed
Fann JR, Hubbard RA, Alfano C, Roth-Roemer S, Katon WJ, and Syrjala KL. Pre- and post-transplantation risk factors for delirium onset and severity in patients undergoing hematopoietic stem cell transplantation. J Clin Oncol 2011 Mar 1;29(7):895-901. Epub 2011 Jan 24. PubMed
Melissa L. Anderson, MSPrincipal Collaborative Biostatistician |
Erin J. Bowles, MPHDirector, Collaborative Science |
Jessica Chubak, PhDSenior Investigator |
Yates Coley, PhDAssociate Biostatistics Investigator |
Andrea J. Cook, PhDSenior Biostatistics Investigator |
Marlaine Figueroa Gray, PhDAssistant Investigator |
Beverly B. Green, MD, MPHSenior Investigator |
Laura E. Ichikawa, MSPrincipal Collaborative Biostatistician |
Jennifer B. McClure, PhDDirector, Investigative Science |
Ellen O'Meara, PhDPrincipal Collaborative Scientist |
Lorella Palazzo, PhDSenior Collaborative Scientist |
Gaia Pocobelli, PhDSenior Collaborative Scientist |
Rod L. Walker, MSPrincipal Collaborative Biostatistician |
Robert D. Wellman, MSPrincipal Collaborative Biostatistician |
Karen Wernli, PhDSenior Investigator |
Onchee Yu, MSPrincipal Collaborative Biostatistician |
Weiwei Zhu, MSSenior Collaborative Biostatistician |
Yu-Ru Su, PhDAssociate Biostatistics Investigator |
Brian D. Williamson, PhDAssistant Biostatistics Investigator |
Noorie Hyun, PhDAssociate Biostatistics Investigator |
Pamela A. Shaw, PhD, MSSenior Biostatistics Investigator |
Nicole M. Gatto, PhD, MPHPrincipal Collaborative Scientist |
Meagan C. Brown, PhD, MPHAssistant Investigator |
Nora Henrikson, PhD, MPHAssociate Investigator |
Lily N. Shapiro, PhDCollaborative Scientist |
Wylie Burke, MD, PhD
University of Washington (UW) Department of Medical History and Ethics
Joann G. Elmore, MD, MPH
Harborview Medical Center; UW Department of Epidemiology
Larry Kessler, ScD
UW Department of Health Services
Constance D. Lehman, MD, PhD
Seattle Cancer Care Alliance; UW Department of Radiology
Kathy Leppig, MD
Kaiser Foundation Health Plan of Washington; UW Department of Pathology
Peggy L. Porter, MD
Fred Hutchinson Cancer Research Center (FHCRC); UW Department of Pathology
Emily White, PhD
FHCRC; UW Department of Epidemiology
Rachel Winer, PhD, MPH
Fred Hutchinson/UW Cancer Consortium; UW Department of Epidemiology